What's new? Pancreatic ductal adenocarcinoma (PDAC) has two distinct subtypes: classical/progenitor and basal-like/squamous, with the latter being more aggressive and exhibiting worse outcomes. Here, the authors probed the transcriptome and metabolome and identified endosome–lysosome associated apoptosis and autophagy regulator 1 (ELAPOR1) as a candidate...

What's new? Circulating tumor DNA (ctDNA) contains genetic mutations specific to the tumor, but not all mutations work equally well as ctDNA markers. Here, the authors show that choosing mutations based on three key features—cancer cell fraction, error rate, and multiplicity—gave the best success in detecting ctDNA. They also make available a bioinformatic...

What's New? Recent reports have suggested an association between the cyclin-dependent kinase 4/6 inhibitor, palbociclib and medication-related osteonecrosis of the jaw; however, reports on this association are inconsistent. This study investigated oral adverse events in patients taking cyclin-dependent kinase 4/6 inhibitors, using spontaneous reports...

What's new? Preclinical and clinical evidence suggests that patients with melanoma may benefit from treatment with PARP inhibitors. Here, the authors show that melanoma cells with high basal PARP1 expression exhibit increased cell death after treatment with PARP inhibitors compared with melanoma cells with low basal PARP1 expression. Moreover, melanomas...

What's new? Chimeric RNAs play crucial roles in human tumors, highlighting the need to investigate their formation mechanism from a novel perspective, such as somatic mutations, to better understand tumor pathogenesis. Our project is pioneering in proposing the examination of the relationship between somatic single nucleotide variants and chimeric...

International Journal of Cancer, Volume 154, Issue 12, Page 2025-2030, 15 June 2024.